正在載入 LIMNW 的資料（首次造訪，需要幾秒鐘）。
Liminatus Pharma, Inc.（LIMNW）股價、分析與資料
您正在查看免費總覽
建立免費帳戶，探索更多關於此標的的研究資料。
指標
關於 Liminatus Pharma, Inc.
查看公司資料 →Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.